These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 29953923

  • 1. The soluble form of LOTUS inhibits Nogo receptor type 1-mediated signaling induced by B lymphocyte stimulator and chondroitin sulfate proteoglycans.
    Kawakami Y, Saito Y, Nakagawa R, Kurihara Y, Takei K.
    Neurosci Lett; 2018 Sep 14; 683():61-68. PubMed ID: 29953923
    [Abstract] [Full Text] [Related]

  • 2. The Soluble Form of LOTUS inhibits Nogo Receptor-Mediated Signaling by Interfering with the Interaction Between Nogo Receptor Type 1 and p75 Neurotrophin Receptor.
    Kawakami Y, Kurihara Y, Saito Y, Fujita Y, Yamashita T, Takei K.
    J Neurosci; 2018 Mar 07; 38(10):2589-2604. PubMed ID: 29440387
    [Abstract] [Full Text] [Related]

  • 3. LOTUS suppresses axon growth inhibition by blocking interaction between Nogo receptor-1 and all four types of its ligand.
    Kurihara Y, Iketani M, Ito H, Nishiyama K, Sakakibara Y, Goshima Y, Takei K.
    Mol Cell Neurosci; 2014 Jul 07; 61():211-8. PubMed ID: 25034269
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The carboxyl-terminal region of Crtac1B/LOTUS acts as a functional domain in endogenous antagonism to Nogo receptor-1.
    Kurihara Y, Arie Y, Iketani M, Ito H, Nishiyama K, Sato Y, Nakamura F, Mizuki N, Goshima Y, Takei K.
    Biochem Biophys Res Commun; 2012 Feb 10; 418(2):390-5. PubMed ID: 22281491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition.
    Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J, Hofer T, Mage RG, Rader C, Giger RJ.
    J Neurosci; 2009 May 06; 29(18):5768-83. PubMed ID: 19420245
    [Abstract] [Full Text] [Related]

  • 12. Versican V2 and the central inhibitory domain of Nogo-A inhibit neurite growth via p75NTR/NgR-independent pathways that converge at RhoA.
    Schweigreiter R, Walmsley AR, Niederöst B, Zimmermann DR, Oertle T, Casademunt E, Frentzel S, Dechant G, Mir A, Bandtlow CE.
    Mol Cell Neurosci; 2004 Oct 06; 27(2):163-74. PubMed ID: 15485772
    [Abstract] [Full Text] [Related]

  • 13. NgR1 and NgR3 are receptors for chondroitin sulfate proteoglycans.
    Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL, Wood A, Geoffroy CG, Zheng B, Liepmann CD, Katagiri Y, Benowitz LI, Geller HM, Giger RJ.
    Nat Neurosci; 2012 Mar 11; 15(5):703-12. PubMed ID: 22406547
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp.
    Wang KC, Kim JA, Sivasankaran R, Segal R, He Z.
    Nature; 2002 Nov 07; 420(6911):74-8. PubMed ID: 12422217
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth.
    Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z.
    Nature; 2002 Jun 27; 417(6892):941-4. PubMed ID: 12068310
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.